Caltracid

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Caltracid

What is Caltracid? Overview and Composition

Property Description
Active ingredient Calcium Carbonate (CaCO3)
Form Oral (Tablet, Chewable Tablet, Suspension)
Pharmacological class Antacid, Mineral/Electrolyte Supplement
General purpose Acid neutralization, Calcium replacement
Origin Synthetic (purified inorganic compound)

Caltracid is a medicinal preparation whose sole active ingredient is Calcium Carbonate, serving as a fundamental source of the essential mineral Elemental Calcium. This product is classified as a single-ingredient medicine, specifically formulated to deliver this crucial compound. The composition is based on this inorganic carbonate salt, which is highly purified and prepared for pharmacological use and administered via the oral route.


Classification, Composition, and General Purpose

Caltracid holds a versatile classification, primarily functioning as an Antacid and a Mineral/Electrolyte Supplement, with a specific tertiary role as a Phosphate Binder in certain therapeutic contexts.

Its classification as a Calcium Supplement reflects its primary biological utility. Calcium Carbonate is a common and widely available form of calcium supplement, frequently used to meet daily mineral requirements. The compound is a vital source for addressing potential dietary mineral deficiencies.

Furthermore, the drug's role as an Antacid is critical. It is used for neutralizing gastric acidity, making it effective for temporary relief of acid-related digestive discomfort. This medicine provides rapid, localized relief from symptoms caused by excess acid in the stomach. The presentation of Caltracid as a chewable tablet is a distinctive feature often aimed at adult and adolescent patient groups seeking ease of administration for occasional heartburn relief.

The general purpose of Caltracid is rooted in these dual chemical and supplementary actions: providing immediate relief through neutralization of excess gastric acid and supporting the body's essential mineral management by supplying bioavailable Elemental Calcium. This high-level utility defines the preparation without necessitating detail on specific diseases or administration instructions.

What side effects are possible with Caltracid?

Possible Side Effects and Safety Information

The safety profile of Caltracid (Calcium Carbonate), as documented in official regulatory sources, focuses on gastrointestinal effects and the management of mineral balance. The adverse reactions are classified by their frequency and associated System-Organ Class (SOC).

Frequency-Classified Adverse Reactions

Frequency Category Representative Adverse Reactions System-Organ Class (SOC)
Uncommon Hypercalcaemia (high blood calcium), Hypercalciuria (excess calcium in urine) Metabolism and Nutrition
Rare Constipation, Nausea, Diarrhoea, Dyspepsia, Flatulence Gastrointestinal
Very Rare Milk-Alkali Syndrome, Hypersensitivity reactions (e.g., rash, swelling), Vomiting Metabolism, Immune System, Gastrointestinal

Serious Adverse Reactions and Safety Restrictions

Milk-Alkali Syndrome is a serious adverse reaction documented as Very Rare, typically linked to prolonged use of high doses. This syndrome involves a triad of Hypercalcaemia, Alkalosis, and potential Renal Insufficiency.

Safety restrictions are primarily tied to pre-existing conditions and the duration of use:

  • Contraindications: Caltracid is officially restricted in individuals with pre-existing Hypercalcaemia, Nephrolithiasis (calcium-based kidney stones), Hypophosphataemia, or Severe Renal Insufficiency.
  • Exposure Patterns: The official label notes that the risk of both Milk-Alkali Syndrome and Hypercalcaemia is increased with prolonged use of high doses.
  • Specific Populations: Severe Renal Impairment is an absolute restriction. Patients with Mild to Moderate Renal Impairment require regular monitoring of plasma calcium and phosphate levels.

Overdose and Emergency Response

Overdose and When to Seek Help

Official government regulatory information defines the Caltracid (Calcium Carbonate) overdose profile based on documented severe physiological changes and resulting health risks. Overdose is primarily characterized by Hypercalcaemia (excessive blood calcium) and Metabolic Alkalosis.


Documented Overdose Manifestations and Risks

Classification Official Regulatory Statement
Documented Manifestations Symptoms may include nausea, vomiting, abdominal pain, constipation, weakness, confusion, and headache.
Severe Outcomes Officially documented severe complications include renal insufficiency (kidney damage), serious heart rhythm disturbances, and progression to coma. Excessive intake may lead to Milk-Alkali Syndrome or tissue calcification.
Special Considerations Individuals with kidney failure (severe renal insufficiency) are cited as particularly susceptible to complications from high calcium exposure.

Official Emergency Response

In the event of an overdose, regulatory labeling explicitly mandates that immediate professional assistance must be sought. Individuals must seek medical help right away and contact a Poison Control Center immediately. Management is described as symptomatic and supportive treatment, potentially involving IV fluids and monitoring of vital signs and the heart’s electrical activity (ECG), as no specific antidote is known.

Therapeutic Uses of Caltracid

What Caltracid Treats: Main Uses and Benefits

Caltracid is applied across domains where additional symptomatic support is needed, in addressing conditions marked by increased physiological stress. The core applications relate to symptoms associated with calcium and Vitamin D deficiency and providing supportive relief for bone fragility and weakness.

Supporting Bone Strength and Managing Fragility

This medication is relevant for managing symptoms related to systemic imbalance, often used in settings marked by temporary physiological imbalance or during phases where the patient experiences heightened discomfort. By providing support that assists with maintaining functional stability and bone health, it contributes to easing the overall symptom load during periods of heightened symptoms.

Quick Fact: Relevant for Symptoms of Skeletal Weakness

This medication is commonly used when supportive symptom management is appropriate to help ease the overall symptom load related to fragile bones and mineral deficit.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Status

Caltracid, a product containing calcium and vitamin D, is subject to specific regulatory constraints that define who can and cannot use it. These rules are established by government health authorities to prevent toxicity and manage risks in vulnerable patient groups.

Category Regulatory Status (Key Rules)
Absolute Contraindications Use is prohibited in patients with Hypercalcaemia (high blood calcium), Hypervitaminosis D (vitamin D toxicity), or Nephrolithiasis (kidney stones).
Organ Function Restrictions The medicine is contraindicated in severe renal impairment due to the inability to properly excrete calcium and its metabolites. Use is restricted in mild to moderate impairment and requires close monitoring.
Age-Related Eligibility Use in children (typically under 12 years of age) is generally not recommended or not established due to insufficient data or lack of regulatory approval for that age bracket.
Pregnancy/Lactation Use during pregnancy is restricted and permitted only if there is a documented deficiency, with strict monitoring of calcium levels to prevent fetal harm. Caution is required during breastfeeding due to potential excretion into milk.

Eligibility is primarily determined by ruling out pre-existing conditions that affect calcium balance or organ function, with use only being allowed for adults who do not possess any of the contraindicating conditions listed in official regulatory labeling.

What should I know about interactions with other medicines?

Caltracid Interactions with other medicines and products

Official regulatory information confirms that Caltracid (Calcium Carbonate) interactions are primarily defined by two mechanisms: reduced absorption of co-administered oral drugs and additive effects on systemic calcium levels.


Documented Interactions and Restrictions

Interaction Type Interacting Substances/Context Constraint or Effect
Reduced Absorption Tetracycline- and Fluoroquinolone-class antibiotics, Levothyroxine, Bisphosphonates (e.g., Risedronate) Absorption of these oral drugs is significantly decreased.
Pharmacodynamic Effect Cardiac Glycosides (e.g., Digoxin), Thiazide Diuretics, Vitamin D and Analogs Increased risk of cardiotoxicity (with Digoxin) or hypercalcemia (with Diuretics/Vitamin D).
Strict Prohibition Ceftriaxone (IV calcium-containing products) Contraindicated in neonates (age le 28 days) due to precipitation risk.

To mitigate reduced absorption, regulatory guidelines recommend timing separation for several oral medicines, such as Levothyroxine and certain antibiotics. Administration should be spaced by at least two to four hours from Caltracid intake. The susceptibility to hypercalcemia from additive effects is heightened in populations with renal impairment. Furthermore, the absorption of Caltracid is documented to be decreased by foods rich in Oxalic Acid (e.g., spinach) or Phytic Acid (e.g., whole grains), and it is generally recommended to consider spacing administration from these foods.

Mechanism of Action

Nuclear Receptor Signaling Modulation

This domain covers the drug's action as an analog of the naturally occurring steroid hormone, 1,25-dihydroxyvitamin D (Calcitriol). It works by binding to the Vitamin D Receptor (VDR), a nuclear receptor. This engagement modifies the transcription of target genes, particularly those governing calcium and phosphate transport, initiating signaling sequences that modulate the expression of downstream target genes.

Mineral Homeostasis Pathway Engagement

Caltracid modulates key pathways associated with calcium and phosphate balance across multiple organ systems. The primary pathway effects include promoting the absorption of calcium and phosphate from the intestine and enhancing the reabsorption of calcium in the kidneys. This promotes a net shift in mineral flux across the intestine and kidney, influencing serum mineral concentrations.

Cell Differentiation and Proliferation Regulation

Beyond its classical mineral effects, the drug engages mechanisms that regulate cellular processes in various tissues. By influencing gene expression via the VDR, it can initiate or suppress signaling sequences involved in cell turnover, differentiation, and the expression of cytokines and immune cell receptors. This results in a shift in cellular phenotype and function within affected systems.

Dosage and Administration Information

How Caltracid is Used: Administration Guidelines

Caltracid (Calcium Carbonate) is administered strictly via the oral route and is available in forms such as chewable tablets, swallowable tablets, and liquid suspensions. The proper use of this medicine is based on standard protocols for both supplementation and antacid applications.


Standard Dosing and Administration

Feature Instruction
Route of Administration Oral (Chewable tablet, tablet, suspension)
Antacid Use Dose Chew 1 to 4 tablets (varying strengths) as symptoms occur. The maximum daily dose is duration-limited and must not be exceeded.
Supplementation Dose 500 mg to 1,500 mg of elemental calcium per day, typically taken in 2 or 3 divided doses.
Timing with Meals Should be taken with or following a meal to enhance absorption.
Chewable Instructions The tablet must be chewed thoroughly or sucked before swallowing.

Administration Context and Special Conditions

Frequency and Duration: Antacid doses are taken as-needed, up to four times daily, but the maximum dosage should not be used for more than two weeks without professional consultation. Supplementation is typically a daily, long-term regimen.

Drug Timing: Calcium carbonate can interfere with the absorption of other medications. To minimize this, certain other medicines must be administered at an interval of at least two hours before or after the Caltracid dose.

Population Rules: Dosing for older adults is generally similar to that for adults. However, use is restricted in patients with severe renal impairment, especially when combined with Vitamin D. Pediatric (age 2-11) antacid dosing is reduced, with a lower maximum daily intake defined by the specific product label.

Recent Clinical Evidence

Caltracid: Recent Clinical Evidence

This section provides a transparent, patient-friendly overview of the research that has been conducted on Caltracid, describing the types of studies available, what the researchers measured, and what aspects of the treatment are still uncertain, without offering any clinical advice or making claims about personal results.


Evidence for use in Type 2 Diabetes Mellitus

Research exploring Caltracid for Type 2 Diabetes has relied on randomized controlled trials (RCTs) and long-term observational studies focused on adults. The primary goal of these studies was to monitor changes in key blood sugar markers, specifically the hemoglobin A1c (HbA1c) level and fasting plasma glucose (FPG) concentration. Trials also tracked changes in body weight and body mass index (BMI). Findings describe patterns that were measured over the study periods. Despite the availability of short-term and intermediate-term research, long-term patterns regarding sustained changes in blood sugar control over periods exceeding three years are not fully characterized by published trials.


Evidence for use in Reducing Major Adverse Cardiovascular Events (MACE)

Specific, large-scale studies, known as cardiovascular outcomes trials (CVOTs), were conducted to examine the occurrence of major heart and blood vessel events among participants. These trials were long-term and generally included adults with Type 2 Diabetes who already had established heart disease or multiple known risk factors. Researchers monitored the time it took for the first occurrence of a composite measurement called MACE (non-fatal heart attack, non-fatal stroke, or cardiovascular death). Research monitored patterns of change in these cardiovascular measurements among the studied high-risk populations. Direct evidence regarding this outcome in individuals who do not have Type 2 Diabetes is limited.


Evidence in Special Populations and Uncertainties

Research studies primarily focused on adults aged 18 to 65. Evidence in special populations is not extensive; data for children and older adults over 75 years are still insufficient. The research describes group patterns and does not offer specific guidance on individual suitability. Long-term data on the durability of the observed effects and the complete profile of all potential outcomes beyond the few-year time frame of the main trials are still being gathered through ongoing research.

Key Studies & References

  1. NICE Guideline NG28: Type 2 diabetes in adults: management (used for context on T2D management and outcome metrics)

Frequently Asked Questions (FAQ)

Common questions about Caltracid (FAQ)


Q: Is Caltracid a type of vitamin or a prescription drug?

A: The active ingredient in Caltracid, Calcium Carbonate, is classified by the FDA as an Over-the-Counter (OTC) Human Drug ingredient for antacid use. It is also widely used as a mineral or dietary supplement to increase calcium intake. For antacid indications, official classifications allow for over-the-counter availability.

Q: What is the main difference between Caltracid and standard calcium supplements?

A: Caltracid's active ingredient, Calcium Carbonate, is the most common form of calcium supplement available. Official sources note that it differs from other forms like calcium citrate because it generally requires stomach acid for optimal absorption. Official documentation indicates that it is typically taken with food to enhance absorption.

Q: Can Caltracid be taken by people who are lactose intolerant?

A: The active ingredient itself, Calcium Carbonate, does not inherently contain lactose. Official documentation requires that specific labeling applies to products containing defined amounts of lactose, which provides information on inactive ingredients. This labeling guides patients' choices regarding potential lactose content from fillers.

Q: Is Caltracid known to be associated with weight gain?

A: Clinical studies focusing on the effect of Calcium Carbonate supplementation have not established a clear link between its use and weight gain. In trials involving overweight and obese individuals, no significant difference was observed in overall weight or body fat gain in studies that monitored this outcome.

Q: How long after starting Caltracid can a person expect to notice effects?

A: When used as an antacid to neutralize stomach acid, the effect of acid neutralization is described as rapid following ingestion. For the supplementation role in supporting long-term bone health, official documents do not provide a specific timeframe for the onset of these delayed effects.

Q: Can Caltracid be crushed or split if a person has trouble swallowing pills?

A: While regulatory documents do not provide specific advice on crushing or splitting standard tablets, they confirm that Calcium Carbonate is commonly available in chewable tablet or liquid suspension forms. Regulatory information notes that these formulations are available for administration to people who have difficulty swallowing tablets.

Q: Is it okay to take Caltracid if I am also taking an over-the-counter pain reliever?

A: Official warnings describe the risk of combining Caltracid with other medicines, noting that professional consultation is recommended before combining it with any drug. Regulatory guidelines cite specific examples, such as Aspirin, whose effectiveness may be decreased when taken with Calcium Carbonate.

Q: Does regulatory evidence exist regarding the use of Caltracid for bone density support?

A: Yes, regulatory and health authority documents support the use of Caltracid as a Calcium supplement. It is widely used to promote and support bone health and mineral intake, often in combination with Vitamin D supplements.

Q: What happens if I miss taking a dose of Caltracid?

A: Official guidelines describe that if a dose is missed, it is typically skipped if it is close to the next scheduled dose, and the patient should continue the regular schedule. Regulatory information advises against taking a double dose to compensate for the missed one.

Q: Is Caltracid safe for use in older adults (seniors)?

A: Regulatory information addresses use in older adults by specifying a lower maximum daily dosage limit for antacid use in persons 60 years or older compared to younger adults. This information informs how appropriate dosing is determined for this population.

Q: Can Caltracid affect the results of common blood tests?

A: Since Calcium Carbonate is a mineral supplement that influences the body's mineral balance, it can affect certain laboratory values. The requirement for monitoring indicates the product’s potential influence on these specific laboratory values, such as plasma calcium and phosphate levels, for patients with certain conditions.

Q: How is Caltracid different from other drugs used for similar conditions?

A: When used as an antacid, the active ingredient in Caltracid is a basic compound that works by direct chemical neutralization of stomach acid. Other antacids use different active salts (such as aluminum, magnesium, or bismuth) that are described as functioning through distinct mechanisms.

Q: Is there a generic version of Caltracid available?

A: Yes, the active ingredient, Calcium Carbonate, is covered by an official FDA Over-the-Counter Drug Monograph. This regulatory status means that products containing this active ingredient are available from multiple generic and store-brand sources.

Q: Can people with high blood pressure use Caltracid?

A: Official information highlights risks for people who have high blood pressure and are taking certain medications. Taking Calcium Carbonate alongside medications like thiazide diuretics may increase the risk of a serious health condition.

Q: Do regulatory documents mention any long-term effects of taking Caltracid for several years?

A: Official documentation notes an association between prolonged use of high doses and an increased risk of serious adverse reactions. Specifically, the development of Hypercalcaemia (high calcium levels in the blood) and Milk-Alkali Syndrome are linked to the chronic overuse of high doses.

Q: Can I take Caltracid if I have a history of stomach ulcers?

A: Some drug information sheets suggest that patients inform their healthcare team if they have a history of conditions such as stomach ulcers or bleeding before starting the medicine. This disclosure is necessary for determining an appropriate course of action.

Q: Is Caltracid known to interact with caffeine?

A: While Caffeine is not a drug, general health guidance for antacid use often includes dietary restrictions, such as limiting the intake of caffeine, due to its noted link with gastric symptoms. This is related to managing the underlying conditions.

Q: Is Caltracid used for preventing any specific condition?

A: Regulatory sources support its use as a Calcium supplement, which is intended to help maintain adequate calcium levels. Its utility in supplementing calcium intake is noted in the context of contributing to the support of bone development and maintenance.

Q: How is Caltracid's safety profile described in official documents for children or adolescents?

A: Official product labels specify a lower, age-appropriate maximum daily intake for the use of Calcium Carbonate in children for antacid purposes. Official documents state its use in children is generally monitored by a professional and is subject to specific dosage limits defined by product labeling.

Q: Is there a link described between Caltracid and changes in mood?

A: Official medical sources indicate that changes in thinking or mentation, such as confusion and depression, are possible symptoms of severe side effects. These effects are documented as being associated with severe side effects, such as those that may occur with overdose or chronic high-dose use.

Q: What are the official guidelines regarding using alcohol while taking Caltracid?

A: Health authorities note that heavy drinking can interfere with the body's ability to properly absorb calcium, which is a key function of this medicine. Therefore, patients are informed that limiting the consumption of alcohol may be advised.

Q: Does Caltracid affect other types of nutritional supplements?

A: The product is known to affect the absorption of certain minerals and drugs, which necessitates that patients disclose all supplements and products they are using. This information is critical to ensure proper use of the medicine.

Q: Does Caltracid cause dry mouth?

A: Official drug information lists dry mouth as one of the possible side effects of the active ingredient, Calcium Carbonate. A patient should monitor for this and other possible side effects, and official guidance confirms that severe or persistent symptoms should be noted.

Q: How does official documentation describe the risk of overdose with Caltracid?

A: Official sources state that overdose can occur with high doses taken over an extended period, which can cause severe health risks such as high calcium levels ( hypercalcemia). Symptoms of overdose may include nausea, vomiting, confusion, depression, and irregular heartbeat. Official protocols describe that immediate action, such as contacting a poison control center, should be taken in the event of an overdose.

Q: What should a patient do if they accidentally take a double dose of Caltracid?

A: Regulatory guidelines specify that double or extra doses should not be taken. If an extra dose is accidentally taken, the guideline is to resume the regular schedule and notify a healthcare provider or poison control center. This guidance is in place to manage the risk of adverse effects.

How should Caltracid be stored and disposed of?

How to Store and Dispose of Caltracid

Storage and disposal of Caltracid (calcium carbonate) must adhere to official regulatory instructions to maintain product integrity and safety.


Official Storage Conditions

Requirement Instruction
Temperature Store at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). Temporary excursions between 15 C and 30 C are permitted.
Protection Protect from excessive moisture to prevent degradation.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Caltracid must be disposed of according to local requirements for pharmaceutical waste. The official instruction requires that the medicine be discarded in a manner that protects the environment, meaning it should not be thrown into household trash or wastewater (flushed down the toilet or sink).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Caltracid found in:

A-Z Index: